SCHEMBL3819065

SCHEMBL3819065

Cc1cc(SCc2oc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 20/20 1.00
PPARA Q07869 8/20 1.00
PPARG P37231 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6235983 0.91 PPARD (0.83) PPARDPPARAPPARG
SCHEMBL4680724 0.90 PPARD (0.82) PPARDPPARAPPARG
SCHEMBL5515760 0.90 PPARD (0.82) PPARDPPARAPPARG
SCHEMBL6238041 0.88 PPARD (1.00) PPARDPPARAPPARG
SCHEMBL6265434 0.84 PPARD (0.71) PPARDPPARAPPARG
Gw501516 SCHEMBL21391885 0.84 PPARD (0.71) PPARDPPARAPPARG
SCHEMBL6238213 0.84 PPARD (1.00) PPARDPPARAPPARG
SCHEMBL5861681 0.84 PPARD (0.72) PPARDPPARAPPARG
SCHEMBL3920736 0.83 PPARD (0.71) PPARDPPARAPPARG
SCHEMBL3919912 0.83 PPARD (0.71) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013134626-A1 PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA AGONIST PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-09-12 WO claimed
EP-1189895-B1 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM CORP (US) 2005-06-08 EP claimed
US-6710063-B1 Activators of PPAR delta SMITHKLINE BEECHAM CORPORATION 2004-03-23 US claimed
US-20030077298-A1 Activators and ligands of PPAR-beta/delta for the treatment of skin conditions THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION 2003-04-24 US claimed
WO-2002083131-A1 ACTIVATORS AND LIGANDS OF PPAR-BETA/DELTA FOR THE TREATMENT OF SKIN CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-10-24 WO claimed
WO-2013134626-A1 PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA AGONIST PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-09-12 WO disclosed
EP-1819681-B1 7-(2H-PYRAZOL-3-YL)-3,5-DIHYDROXY-HEPTANOIC ACID DERIVATIVES AS HMG CO-A REDUCTASE INHIBITORS FOR THE TREATMENT OF LIPIDEMIA WARNER LAMBERT CO (US) 2009-08-12 EP disclosed
US-20090170852-A1 NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS PFIZER INC. 2009-07-02 US disclosed
US-7446121-B2 Pyrazole-based HMG CoA reductase inhibitors PFIZER INC. (US) 2008-11-04 US disclosed
US-20080227974-A1 Novel Substituted Azetidinones PFIZER INC. 2008-09-18 US disclosed
WO-2008104875-A1 OXAZOLIDINONES AS CHOLESTEROL ABSORPTION INHIBITORS PFIZER PRODUCTS INC. (US) 2008-09-04 WO disclosed
EP-1912937-A1 NOVEL SUBSTITUTED AZETIDINONES Warner-Lambert Company LLC (US) 2008-04-23 EP disclosed
EP-1189895-B1 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM CORP (US) 2005-06-08 EP disclosed
US-6723740-B2 ADMINISTERING THERAPEUTIC AMOUNT OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST TO LOWER TRIGLYCERIDES SMITHKLINE BEECHAM CORPORATION 2004-04-20 US disclosed
US-6710063-B1 Activators of PPAR delta SMITHKLINE BEECHAM CORPORATION 2004-03-23 US disclosed
US-20030203947-A1 Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides CHAO ESTHER YU-HSUAN (US) 2003-10-30 US disclosed
US-20030077298-A1 Activators and ligands of PPAR-beta/delta for the treatment of skin conditions THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION 2003-04-24 US disclosed
WO-2002083131-A1 ACTIVATORS AND LIGANDS OF PPAR-BETA/DELTA FOR THE TREATMENT OF SKIN CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-10-24 WO disclosed
EP-1189895-A1 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE GLAXO GROUP LIMITED (GB) 2002-03-27 EP disclosed
WO-2001000603-A1 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE GLAXO GROUP LIMITED (GB) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170852-A1 NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS HMGCR, BPHL, CYP46A1 PPARD 182/4885PPARA 123/4885PPARG 141/4885
US-20030203947-A1 Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides PPARA, PPARD, PPARG PPARD 2/4885PPARA 1/4885PPARG 3/4885
US-20030077298-A1 Activators and ligands of PPAR-beta/delta for the treatment of skin conditions PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885PPARG 1/4885
US-20080227974-A1 Novel Substituted Azetidinones APOB, PCSK9, CYP46A1 PPARD 278/4885PPARA 695/4885PPARG 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.